A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants With Diabetic Macular Edema (DME)
Latest Information Update: 31 May 2024
At a glance
- Drugs RZ 402 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Rezolute
- 21 May 2024
- 21 May 2024 According to a Rezolute media release,Arshad Khanani, MD, MA, FASRS, Clinical Professor at the Reno School of Medicine, University of Nevada is a Primary Investigator of the study
- 21 May 2024 Primary endpoint (Change in Central Subfield Thickness [ Time Frame: 12 weeks ]) has been met.